Skip to main content
PACIFIC EDGE LIMITED logo

PACIFIC EDGE LIMITED — Investor Relations & Filings

Ticker · PEB ISIN · NZPEBE0002S1 LEI · 9845007EDCF068FFEA12 ASX Professional, scientific and technical activities
Open in API
Filings indexed 745 across all filing types
Latest filing 2026-05-25 Share Issue/Capital Cha…
Country NZ New Zealand
Listing ASX PEB

About PACIFIC EDGE LIMITED

https://www.pacificedgedx.com/

Pacific Edge Limited is a cancer diagnostics company specializing in the development and commercialization of non-invasive molecular diagnostic tests. The company's primary product suite, Cxbladder, utilizes advanced mRNA biomarker technology to detect and monitor bladder cancer from urine samples. These genomic tests are designed to assist clinicians in the evaluation of patients presenting with hematuria and in the ongoing surveillance of patients previously diagnosed with the disease. By providing high sensitivity and negative predictive value, the Cxbladder suite helps to accurately rule out urothelial carcinoma, potentially reducing the requirement for invasive clinical procedures such as cystoscopy. The company focuses on integrating its diagnostic tools into standard clinical pathways to improve patient outcomes and healthcare efficiency.

Recent filings

Filing Released Lang Actions
Retail Offer to Close 28 May 2026; Likely to be Scaled
Share Issue/Capital Change Classification · 85% confidence The document is a public announcement by Pacific Edge regarding a retail offer of new shares to existing shareholders to raise up to NZ$6 million. It details subscription limits, record date, scaling of applications, closing date, and related rules under NZX Listing Rules. This is clearly an announcement of a new share issue (capital change) rather than a full financial report or simple publication notice. Therefore, it is classified as a Share Issue/Capital Change.
2026-05-25 English
Advancing Medicare Coverage Goals; Cost Contained
Earnings Release Classification · 87% confidence The document is a press release announcing Pacific Edge’s audited FY26 financial results, including key financial metrics (revenue, net loss, cash burn), strategic highlights, outlook, capital raising details, and a conference call. It is not the full Annual Report or an interim report, but an initial summary announcement of periodical financial results, fitting the Earnings Release category. FY 2026
2026-05-24 English
Advancing Medicare Coverage Goals Cost Contained 81 pages 3.6MB
Investor Presentation Classification · 90% confidence The document is a detailed slide‐style presentation (with slide numbers, headings, an “Important Notice and Disclaimer” section) released alongside FY26 audited financial results, strategic highlights, CEO/CFO commentary, and a conference call invitation. It goes beyond a brief earnings release by including a full investor slide deck to illustrate performance, strategy, and outlook. This matches the Investor Presentation category.
2026-05-24 English
Retail Offer Reminder 2 pages 151.4KB
Capital/Financing Update Classification · 90% confidence The document is a public announcement regarding a retail offer to existing shareholders to raise up to NZ$6 million, providing details on subscription, record dates, scaling, and use of placement capacity. It is an update on the company’s fundraising and capital structure, not a full financial report or a brief earnings release. Therefore it falls under “Capital/Financing Update” (CAP).
2026-05-24 English
D&O Disclosures - Multiple
Director's Dealing Classification · 98% confidence The document is an NZX Ongoing Disclosure Notice under sections 297–298 of the Financial Markets Conduct Act, detailing a director’s acquisition of 2,941,176 ordinary shares, including transaction date, consideration, and holdings before/after. This is a report of personal share transactions by a company director, matching the definition of Director’s Dealing (insider trades).
2026-05-21 English
NZX D&O Disclosures - Multiple 10 pages 4.1MB
Director's Dealing Classification · 95% confidence The document is a continuous NZX ‘Ongoing Disclosure Notice’ under the Financial Markets Conduct Act 2013 requiring directors and senior managers to disclose acquisitions and disposals of share interests. It details multiple insider transactions by named directors. This is a classic insider/dealer report. Therefore, it matches the Director’s Dealing category.
2026-05-20 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.